Pancreatic Cancer Research

ResearcherMedical College of WisconsinActive in the last 2 years

Kulwinder S. Dua

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0460-5595; OpenAlex author ID A5044819265. Sources: ClinicalTrials.gov.

Their work

Papers
14 (first author 0, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 14

  1. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  2. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  3. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  4. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Co-author DOI 10.1007/s10555-021-09993-z↗
  5. Advanced Endoscopic Techniques for the Diagnosis of Pancreatic Cancer and Management of Biliary and GastricOutlet Obstruction. Last author DOI 10.1016/j.soc.2021.06.005↗
  6. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  7. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
  8. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. Co-author DOI 10.1016/j.gie.2019.06.032↗
  9. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  10. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07906-7↗
  11. Safety and efficacy of self-expanding metal stents for biliary drainage in patients receiving neoadjuvant therapy for pancreatic cancer. Last author DOI 10.1055/a-0599-6190↗
  12. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002957↗
  13. Evolution of the Management of Resectable Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.015818↗
  14. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective st… Last author DOI 10.1016/j.gie.2012.02.041↗

Trials 1

  1. Simple Technique to Improve Diagnostic Yield in EUS-FNA Principal investigator NCT01995474↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Douglas B. Evans · 11 shared papers, 2012–2025 · strength 1.20
  2. Susan Tsai · 10 shared papers, 2016–2025 · strength 1.16
  3. Kathleen K. Christians · 9 shared papers, 2018–2025 · strength 1.09
  4. William Adrian Hall · 8 shared papers, 2018–2025 · strength 1.00
  5. Bradley A. Erickson · 9 shared papers, 2016–2024 · strength 0.95
  6. Mohammed Aldakkak · 7 shared papers, 2019–2025 · strength 0.89
  7. Ben George · 8 shared papers, 2018–2024 · strength 0.88
  8. Callisia Nathelee Clarke · 6 shared papers, 2019–2025 · strength 0.80
  9. Mandana Kamgar · 5 shared papers, 2020–2025 · strength 0.75
  10. Sara Beltrán Ponce · 2 shared papers, 2021–2025 · strength 0.32
  11. Yousuke Nakai · 2 shared papers, 2019–2021 · strength 0.28
  12. Chad A. Barnes · 3 shared papers, 2019–2020 · strength 0.28
  13. Parag P. Tolat · 3 shared papers, 2016–2019 · strength 0.23
  14. Jordan R. Kharofa · 1 shared paper, 2025 · strength 0.20
  15. Ben George · 1 shared paper, 2025 · strength 0.20
  16. E.S. Paulson · 1 shared paper, 2025 · strength 0.20
  17. Beth E. Erickson · 1 shared paper, 2025 · strength 0.20
  18. Kenneth J. Chang · 1 shared paper, 2021 · strength 0.19
  19. Catherine E. Hagen · 2 shared papers, 2019–2020 · strength 0.18
  20. Sakti Chakrabarti · 1 shared paper, 2024 · strength 0.17
  21. Saryleine Ortiz de Choudens · 1 shared paper, 2024 · strength 0.17
  22. Sam Z. Thalji · 1 shared paper, 2023 · strength 0.15
  23. Asfar Sohail Azmi · 1 shared paper, 2021 · strength 0.12
  24. Darren D. Ballard · 1 shared paper, 2018 · strength 0.11
  25. Naveen M. Kulkarni · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.